3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
4
Neoplasms
4
Pulmonary Embolism
2
Lung Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
fludarabine phosphate
34
Cyclophosphamide
34
Peripheral Blood Stem Cell Transplantation
23
Busulfan
22
Mycophenolic Acid
21
Cyclosporine
20
Whole-Body Irradiation
19
Tacrolimus
18
Antilymphocyte Serum
18
Melphalan
16
Filgrastim
16
Radiotherapy
15
Methotrexate
14
fludarabine
12
Cord Blood Stem Cell Transplantation
12
Methylprednisolone
10
Cytarabine
10
Etoposide
8
sargramostim
6
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
5
Alemtuzumab
4
thymoglobulin
3
merphos
3
Tretinoin
3
Thiotepa
3
Thalidomide
3
Sirolimus
3
Rituximab
3
Leucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tinzaparin
×
Classical hematology
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled